NeoGraft selects Verasoni Worldwide as marketing communications partner

NewsGuard 100/100 Score

NeoGraft® is pleased to announce the selection of Verasoni Worldwide as integrated marketing communications partner. NeoGraft® is a world leader in hair replacement technology serving physicians and patients in the United States and around the world. NeoGraft® is the first Class One FDA Listed automated medical device for hair restoration. This system harvests, collects, and implants individual follicular grafts using one user-friendly platform. NeoGraft® provides advances in both hair restoration technology and clinical techniques designed to promote the increase in safety, precision, artistry and efficiency for the benefit of both the patient and the physician. With NeoGraft® patients can enjoy the growth of their own real hair without the unsightly scar associated with the older strip-method.

"We're excited to partner with Verasoni Worldwide for rebranding and global marketing communications. Our rebranding efforts reflect our world-class physician partners and patients. We want to ensure that the NeoGraft® brand continues its aspirational market leadership in the near and long-term, and our new branding and marketing communications shall reflect that," said Glenn Normoyle, President of NeoGraft®. Verasoni Worldwide will work with NeoGraft's marketing leadership on strategy, rebranding, digital campaigns, consumer and business to business public relations, physician communications and consumer marketing.

Abe Kasbo, CEO of Verasoni Worldwide, "I'm delighted to welcome NeoGraft® to our family of clients. NeoGraft® holds a terrific reputation as leaders in Hair Replacement and Transplant Technology. Our entire team is looking forward to helping NeoGraft® amplify its brand as the leading technology in the field," said Abe Kasbo, CEO of Verasoni Worldwide. Sasha Idriss, Head of Global Accounts will be NeoGraft®'s account lead.

SOURCE Verasoni Worldwide

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations